P3, N=140, Active, not recruiting, Sol-Gel Technologies, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026

3 months ago

Enrollment closed • Trial completion date • Trial primary completion date

PTCH1 (Patched 1)

patidegib topical (SGT-610)

1year

Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome. (PubMed, Br J Dermatol)

Patidegib Topical Gel warrants further clinical development.

1 year ago

P2 data • Journal

PTCH1 (Patched 1)

PTCH1 mutation

cyclopamine • saridegib oral (IPI 926 oral) • patidegib topical (SGT-610)

almost2years

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (clinicaltrials.gov)

P3, N=140, Recruiting, Sol-Gel Technologies, Ltd. | Not yet recruiting --> Recruiting

almost 2 years ago

Enrollment open

PTCH1 (Patched 1)

PTCH1 mutation

patidegib topical (SGT-610)

2years

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (clinicaltrials.gov)

P3, N=140, Not yet recruiting, Sol-Gel Technologies, Ltd.

2 years ago

New P3 trial

PTCH1 (Patched 1)

PTCH1 mutation

patidegib topical (SGT-610)

over4years

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) (clinicaltrials.gov)

P3, N=174, Completed, PellePharm, Inc. | Active, not recruiting --> Completed

over 4 years ago

Clinical • Trial completion

PTCH1 (Patched 1)

PTCH1 mutation

patidegib topical (SGT-610)